Alerts
CLL Just Moved a Noncovalent BTK Inhibitor Into First Line
FDA has approved pirtobrutinib for previously untreated CLL or SLL without known 17p deletion. The approval pushes a noncovalent BTK inhibitor into first-line care after a Phase III trial produced a striking progression-free survival advantage over chemoimmunotherapy.
New York Had Cooling-Tower Rules. Legionnaires’ Still Broke Through.
ctDNA Is Becoming the New Argument Over Chemotherapy
India Approved Its First Dengue Vaccine. Access Is Still Unwritten.
Myeloma Patients May Not Need Treatment Forever
Canada Chose An Ebola Travel Ban. WHO Warned Against It.
Lung Cancer May Be Entering the Chemo-Replacement Fight
Britain Has A £1 Billion Pandemic Plan.
Bladder Cancer Surgery Just Became a System Test
Cataplexy Is Waiting on an FDA Clock
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.